Literature DB >> 31342104

[Phosphodiesterase inhibitors for the treatment of benign prostatic hyperplasia].

Friedemann Zengerling1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31342104     DOI： 10.1007/s00120-019-1008-0

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


× No keyword cloud information.
  5 in total

1.  Patients not P values.

Authors:  Jonathan Rees
Journal:  BJU Int       Date:  2015-05       Impact factor: 5.588

2.  [Phytotherapy for benign prostatic hyperplasia].

Authors:  Friedemann Zengerling
Journal:  Urologe A       Date:  2018-07       Impact factor: 0.639

Review 3.  Serenoa repens for benign prostatic hyperplasia.

Authors:  James Tacklind; Roderick Macdonald; Indy Rutks; Judith U Stanke; Timothy J Wilt
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

4.  Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?

Authors:  M J Barry; W O Williford; Y Chang; M Machi; K M Jones; E Walker-Corkery; H Lepor
Journal:  J Urol       Date:  1995-11       Impact factor: 7.450

5.  Efficacy of tamsulosin and tadalafil in relieving benign prostatic hyperplasia related symptoms: A randomized double blind placebo controlled cross-over study.

Authors:  Smita Pattanaik; Harbhupinder Singh Sandhu; Ravimohan Suryanarayan Mavuduru; Shrawan Kumar Singh; Arup Kumar Mandal
Journal:  Indian J Urol       Date:  2019 Jan-Mar
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.